Free Trial
NYSE:RVTY

Revvity (RVTY) Stock Price, News & Analysis

$115.41
-1.71 (-1.46%)
(As of 09/6/2024 ET)
Today's Range
$114.92
$118.82
50-Day Range
$102.01
$127.24
52-Week Range
$79.50
$128.15
Volume
643,237 shs
Average Volume
843,269 shs
Market Capitalization
$14.24 billion
P/E Ratio
95.38
Dividend Yield
0.24%
Price Target
$126.00

Revvity MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.61 Rating Score
Upside/​Downside
9.2% Upside
$126.00 Price Target
Short Interest
Bearish
3.46% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$854,350 Sold Last Quarter
Proj. Earnings Growth
9.26%
From $4.75 to $5.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

373rd out of 910 stocks

Analytical Instruments Industry

12th out of 26 stocks

RVTY stock logo

About Revvity Stock (NYSE:RVTY)

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

RVTY Stock Price History

RVTY Stock News Headlines

Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
Revvity (NYSE:RVTY) Now Covered by Wells Fargo & Company
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
Revvity, Inc. Q2 Profit Increases, Beats Estimates
Revvity Raises FY24 Earnings Guidance
See More Headlines
Receive RVTY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 8/9 Dividend
7/19/2024
Last Earnings
7/29/2024
Dividend Payable
8/09/2024
Today
9/07/2024
Next Earnings (Estimated)
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Employees
11,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$126.00
High Stock Price Target
$145.00
Low Stock Price Target
$105.00
Potential Upside/Downside
+9.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
18 Analysts

Profitability

Net Income
$693.09 million
Pretax Margin
7.50%

Debt

Sales & Book Value

Annual Sales
$2.71 billion
Cash Flow
$7.78 per share
Book Value
$63.81 per share

Miscellaneous

Free Float
122,653,000
Market Cap
$14.24 billion
Optionable
Optionable
Beta
1.05
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Prahlad R. Singh Ph.D. (Age 59)
    CEO, President & Director
    Comp: $1.43M
  • Mr. Maxwell Krakowiak (Age 34)
    Senior VP & CFO
    Comp: $631.11k
  • Mr. Tajinder S. Vohra (Age 58)
    Senior Vice President of Global Operations
    Comp: $574.08k
  • Mr. Joel S. Goldberg (Age 55)
    Senior VP of Administration, General Counsel & Secretary
    Comp: $720.74k
  • Ms. Miriame Victor (Age 42)
    Senior VP & Chief Commercial Officer
    Comp: $555.4k
  • Mr. Andrew Okun (Age 54)
    VP, Chief Accounting Officer & Treasurer
  • Mr. Arvind Sundar-Rajan
    Vice President of Digital & Technology
  • Ms. Madhuri Hegde FACMG
    Ph.D., Senior VP & Chief Scientific Officer
  • Ms. Jayashree Thacker
    Senior VP & Global Chief Information Officer
  • Mr. Stephen Barr Willoughby
    Senior VP of Investor Relations & Head of ESG

RVTY Stock Analysis - Frequently Asked Questions

How have RVTY shares performed this year?

Revvity's stock was trading at $109.31 at the beginning of the year. Since then, RVTY shares have increased by 5.6% and is now trading at $115.41.
View the best growth stocks for 2024 here
.

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:RVTY) released its earnings results on Monday, July, 29th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.12 by $0.10. Revvity's revenue was down 2.5% on a year-over-year basis.

Is Revvity doing a stock buyback?

Revvity's board initiated a stock repurchase plan on Thursday, May 11th 2023, which allows the company to repurchase $600,000,000 in shares, according to EventVestor. This means that the company could purchase up to 5.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's management believes its stock is undervalued.

Who are Revvity's major shareholders?

Top institutional shareholders of Revvity include Select Equity Group L.P. (5.97%), EdgePoint Investment Group Inc. (1.62%), Dimensional Fund Advisors LP (0.93%) and Ceredex Value Advisors LLC (0.89%). Insiders that own company stock include Prahlad R Singh and Joel S Goldberg.
View institutional ownership trends
.

How do I buy shares of Revvity?

Shares of RVTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RVTY) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners